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The Organoid Cell Atlas
To the Editor — Human organoids hold 
tremendous potential for biomedical 
applications1–3 (Fig. 1a,b). These 
three-dimensional structures of cultured 
cells recapitulate important aspects of 
in vivo organ development and biological 
function. They provide tractable in vitro 
models of human physiology and pathology, 
thereby enabling interventional studies 
that are difficult or impossible to conduct 
in human subjects. For example, organoids 
allow genetic and pharmacological 
manipulation in a complex cellular context 
that reflects human biology, and they enable 
investigations of the early stages of organ 
development and disease onset. Human 
organoids complement (and may eventually 
replace) animal models in many areas of 
preclinical drug development. Moreover, 
they provide patient-specific ‘avatars’ for 
drug development and precision therapies, 
including treatments for cancer, rare 
genetic diseases (such as cystic fibrosis) and 
complex multifactorial disorders (such as 
epilepsy). Finally, they promise to contribute 
to regenerative medicine, with the goal of 
producing functional biological structures 
that can be transplanted into patients.
To realize the full potential of human 
organoids, key challenges need to be 
addressed (Fig. 1c). Most immediately, we 
need better characterization and validation 
of organoids as faithful models of human 
biology. This will require assays for 
informative high-throughput profiling  
as well as the definition of quality standards 
for cell composition, cellular differentiation, 
cell states and responses to stimuli.  
A future catalog of well-characterized 
human organoids should include extensive 
replication, to quantify technical and 
biological sources of variation. Moreover, 
inclusion of genetically diverse sample 
donors will help to assess interindividual 
variation in the human population.
Current organoid protocols, while 
useful for many applications, have relevant 
technical and conceptual limitations. For 
example, organoids may not faithfully 
represent the diversity of cell types in 
primary tissue (including non-parenchymal 
cells such as immune cells and stroma), 
and they are limited in their ability to 
account for the effects that environmental 
exposures and organismal aging have on 
human organs in vivo. It will be important 
to develop robust protocols that yield 
organoids with adequate tissue organization, 
differentiated cells, vascularization, immune 
cell infiltration and, for some organs 
(for example, skin and intestine), even a 
microbiome. Moreover, we are still learning 
how to use organoids most effectively for 
discovering biology (for example, through 
genetic and pharmacological perturbations) 
and how to exploit them for drug 
development and personalized medicine.
Single-cell sequencing and spatial 
profiling have a key role in addressing 
these issues (Fig. 1d). Comprehensive 
molecular maps of organoids and organoid 
development can reveal cell states and 
transcription regulatory programs in 
unprecedented detail, and comparisons 
to corresponding human tissues in vivo 
provide powerful new ways of evaluating 
organoids. Single-cell epigenome and 
transcriptome profiling yields a quantitative, 
high-dimensional assessment of cell 
composition and cell states within organoids. 
Spatial profiling assays characterize tissue 
organization and three-dimensional 
architecture. These methods also enhance 
organoid quality control (for example, 
identifying outliers, missing cell types or 
aberrant gene regulation), and they can 
provide reference atlases for disease-centric 
studies. Furthermore, comparative 
molecular profiling of organoids and 
matched ex vivo tissue samples can guide 
the development of new and improved 
organoid protocols, for example, by 
identifying missing cell populations or 
bottlenecks of cellular differentiation in 
organoids. Finally, single-cell technologies 
provide a powerful and scalable readout 
for functional experiments and for genetic 
or pharmacological perturbations that are 
tested in human organoids.
To demonstrate the feasibility and 
utility of combining human organoids with 
single-cell technology, we have launched 
an Organoid Cell Atlas pilot project, as a 
‘Biological Network’ within the Human 
Cell Atlas (HCA)4–6, focusing on the 
single-cell characterization of organoids 
and complex in vitro systems (https://
www.humancellatlas.org/coordinators). 
The Organoid Cell Atlas will facilitate the 
production, quality control, dissemination 
and utilization of single-cell and spatial 
genomics data for human organoids, and it 
will link such datasets to the comprehensive 
profiles of primary tissues that are being 
generated within the HCA. A first step 
toward establishing the Organoid Cell Atlas 
has recently been funded by the European 
Union Horizon 2020 call for “Pilot actions  
to build the foundations of a human  
cell atlas” with the ‘HCA|Organoid’  
project (https://hca-organoid.eu).
The Organoid Cell Atlas within the HCA
The Organoid Cell Atlas will be a 
cornerstone of the HCA. It is central  
to the HCA’s mission of creating 
comprehensive reference maps of all  
human cells as a basis for understanding 
human health and for diagnosing, 
monitoring and treating disease. Like the 
Human Genome Project7, the HCA is 
expected to have substantial biomedical 
impact, most notably in areas such as 
precision medicine and regenerative 
biology. Human organoids will be of 
great importance in the HCA6, as they 
complement the profiling of primary tissue 
samples with a readily perturbed model for 
functional studies while also benefitting 
from the profiling of human tissues to  
which they can be compared.
Some of the first applications of 
single-cell profiling in organoids included 
single-cell RNA-seq analysis of the 
cellular composition of mouse intestinal 
organoids8 and human brain organoids9. 
Other pioneering studies uncovered 
complex cellular networks10 and used 
single-cell profiles to improve organoid 
derivation protocols11. These initial reports 
identified striking parallels among organoid 
development, human primary tissue and 
in vivo organogenesis, which reinforces the 
potential of organoids for dissecting human 
biology in vitro.
To exploit synergies between single-cell 
profiling and organoid technologies, the 
Organoid Cell Atlas has been initiated in 
close coordination with the HCA leadership, 
following the example of other specialized 
atlases such as the Pediatric Cell Atlas12 and 
the Human Tumor Cell Atlas Network13. The 
Organoid Cell Atlas is an open, collaborative 
network that pursues four complementary 
directions: first, encourage and standardize 
single-cell profiling of human organoids; 
second, facilitate access to single-cell 
organoid data (and informative metadata) 
via HCA data infrastructure; third, establish 
computational methods and tools for 
connecting organoid profiles with primary 
tissue data; and fourth, put organoids 
into their biological context using HCA 
profiles of their in vivo counterparts. The 
envisioned data integration will be driven by 
an interactive, openly accessible, web-based 
computational platform called the Organoid 
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Cell Atlas Portal, which will build on and 
extend the existing HCA data infrastructure.
An initial version of the Organoid  
Cell Atlas
The European Union Horizon 2020  
(EU H2020) HCA|Organoid project  
enables us to establish a first version of 
the Organoid Cell Atlas over the coming 
years, which may act as a nucleus for a 
broader, collaborative, global initiative. 
In this pilot project, we are generating 
single-cell transcriptome profiles, 
epigenome maps and detailed imaging 
data in a selection of human organoids. 
For two organs, colon and brain, we will 
derive and characterize organoids from 100 
whole-genome-sequenced individuals each, 
to capture normal population variation and 
to establish a reference for disease-centric 
studies (Fig. 2a,b). User-friendly access 
to the single-cell data for organoids and 
comparisons between organoid profiles and 
single-cell data for human primary tissues 
will be available on the Organoid Cell Atlas 
Portal, which is being developed in parallel 
with the data generation.
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a  Two main types of human organoids
c  Challenges in organoid biology
Validate existing 
organoids as robust 
and faithful models 
of human biology 
Develop improved 
organoid models: 
more cell types, better 
differentiation, etc. 
Apply organoids for 
experiments that are 
otherwise impossible 
in human 
d  Contributions of single-cell sequencing
b  Biomedical applications of organoids




• Relatively easy to scale
Example: epithelial colon 
organoids
Validating organoids
• Connect cell types in organoids
 to their counterparts in tissues
• Identify and flag outliers
Improving organoids
• Infer key regulators from single-
 cell profiling data
• Refine protocols and validate 
 by single-cell sequencing 
Applying organoids
• Induce functional perturbations 
 (genetic, pharmacological)
• Assess effects by single-cell
 sequencing




dissection of monogenic 
neurological disorders using 
brain organoids
Patient-specific ‘avatars’ 
for personalized drug 
testing
Example: patient-specific 
testing of expensive drugs for 
cystic fibrosis using rectal 
organoids
Functional biological 
structures for transplantation 
into patients
Example: preclinical testing of 
engineered biological functions 
using lung organoids
Pluripotent stem cell 
derived organoids
• Complex, multi-step protocols
• Technically challenging
• Possible to derive multiple  
 lineages from the same cells
Example: iPSC-derived 
cerebral organoids
Fig. 1 | Combining organoids and single-cell technology for biomedical discovery and regenerative therapy. a, Organoids can be derived from adult stem 
cells, which are already committed to a specific cell lineage, tissue and/or organ, or from pluripotent cells, which can give rise to a broad set of cell types 
but requires more complex differentiation protocols. b, Human organoids are broadly useful for in vitro modeling of biological functions, drug testing and 
regenerative medicine. c, Key challenges for advancing organoid research include characterization and validation of organoids, development of new organoid 
protocols, and applications of organoids in basic biology and biomedical research. d, Single-cell technologies promise to advance organoid research by 
enabling systematic validation of the derived organoids, by informing organoid protocol development, and by providing a high-resolution readout for functional 
perturbation experiments in human organoids.
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We selected colon and brain organoids 
as the two focus areas of the HCA|Organoid 
project for three reasons: first, colon and 
brain were among the first organs for which 
organoids were demonstrated, so relatively 
mature protocols are now available; second, 
colon organoids are derived from adult stem 
cells in primary ex vivo samples while brain 
organoids are derived from pluripotent 
cells, thus spanning the two main sources 
of organoid derivation; third, colon and 
brain organoids have already been used 
for disease-centric studies, and single-cell 
characterization of these organoids for a 
large number of individuals will facilitate 
biomedical applications. Beyond the initial 
focus on colon and brain organoids, the 
HCA|Organoid project is designed in such 
a way that most of the data infrastructure 
is generic and applicable to other types 
of human organoids. We actively seek 
collaboration with other projects that pursue 
systematic single-cell profiling in other 
types of human organoids to explore the 
possibility of interconnection or integration 
with the Organoid Cell Atlas.
The Organoid Cell Atlas Portal is a 
central aim of the EU H2020 HCA|Organoid 
project. It will provide computational 
infrastructure and a web-based front 
a  The Organoid Cell Atlas: translating between organoids and primary tissues
b  Key functions of the Organoid Cell Atlas Portal
Single-cell profiling of human organoids Organoid Cell Atlas Portal and 
single-cell mapping algorithm
Single-cell profiling of human 
primary tissue samples
Pluripotent or adult 
stem cells in vitro
Human organoids Single-cell sequencing and imaging data Living or postmortem 
tissue donors
Advantages: complex organ structure, 
directly reflecting human physiology  
Advantages: experimentally accessible, fewer 
practical and ethical constrains
Primary samples
Infer key regulators that are 
aberrantly expressed in 
organoids vs. primary tissue
Select most suitable organoid 
protocols, clones, time points 
for a given application  
Interpret the results of in vitro 
pertubation experiments in a 
matched in vivo context
Connect and align 
cell types between 
organoids and primary 
tissue samples 
Identify missing cell 
types relative to 
other organoids and 
primary tissues 
Fig. 2 | Connecting single cells in human organoids and in primary tissue samples via the Organoid Cell Atlas. a, Single-cell profiling of human organoids 
(left) and of human primary tissue samples (right) provides complementary information. Data integration between single-cell profiles from organoids and 
primary tissues makes it possible to investigate the same cell type in both contexts, allowing each approach to play to its strengths. b, The Organoid Cell atlas 
Portal will implement key features for analyzing and interpreting single-cell data from human organoids in the biological context provided by HCa profiles of 
their in vivo counterparts.
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end that make single-cell data for human 
organoids easy to access and analyze. This 
effort will build upon the existing Data 
Coordination Platform infrastructure of 
the HCA (https://data.humancellatlas.
org) for data submission, processing, 
annotation and retrieval. Key features that 
are specific to organoids will include the 
interactive exploration of human organoid 
data, data-driven selection of organoids for 
functional experiments, and comparison of 
disease-specific organoids against reference 
collections of normal organoids.
The Organoid Cell Atlas Portal will 
also provide interactive mappings between 
single-cell profiles of human organoids  
and the corresponding primary tissues 
available within the HCA, using algorithms 
that enable cell–cell alignments between 
these datasets. This functionality will 
facilitate and encourage the use of 
organoids as a model for detailed biological 
experiments, including the identification  
of target genes for mechanistic research  
and drug development. The mapping  
and data integration will also allow 
exploration of normal variation between 
individuals (for example, due to common 
genetic differences) in an interactive 
manner, leveraging organoids as a  
model for the corresponding variation in  
primary tissues. Finally, the cell–cell 
alignments will facilitate the analysis 
and interpretation of perturbations in 
human organoids in the context of the 
corresponding primary tissues.
We will pursue several complementary 
strategies to ensure that the data in the 
Organoid Cell Atlas will be of the highest 
possible quality and reproducibility. First, 
we will invest in standardization and 
validation of experimental workflows for 
organoid derivation — for example, by 
comparing alternative protocols and by 
assessing the relative effect of technical and 
biological factors on the single-cell profiles 
of colon and brain organoids. Second, we 
will contribute to HCA efforts to establish 
community standards and software 
infrastructure for data processing and data 
annotation — for example, by ensuring 
compatibility with the specific metadata 
structure for organoids. Third, we will 
develop and validate computational methods 
for the flexible alignment and comparison of 
cells between organoids and corresponding 
primary tissue. Finally, we will implement 
interactive visualization tools that enable 
user-friendly quality control and exploratory 
analysis of single-cell organoid datasets 
contributed to the Organoid Cell Atlas.
To maximize the utility and impact of 
the EU H2020 HCA|Organoid project for 
the broader scientific community, single-cell 
profiles will be made public as rapidly as 
possible, in concordance with the HCA’s 
strong commitment to data sharing, local 
ethical regulations and the European 
data protection law (GDPR). Newly 
established organoids will be provided as 
a ‘living biobank’ via Hubrecht Organoid 
Technology14 (colon) or as a set of precise 
protocols for derivation from biobanked 
induced pluripotent stem cell lines (brain). 
Furthermore, we will evaluate and explore 
the practical utility of the Organoid Cell 
Atlas in a series of disease-centric pilot 
studies, pursuing CRISPR screening 
with single-cell transcriptome readout 
(CROP-seq)15 and disease modeling of 
genetic epilepsy using brain organoids 
selected from the Organoid Cell Atlas. 
Finally, we are committed to developing the 
Organoid Cell Atlas Portal into a public, 
sustainable and widely used infrastructure 
for finding, accessing, analyzing and 
interpreting single-cell data from human 
organoids.
Future directions
With recent technological advances,  
human beings are becoming the leading 
‘model organism’ for the discovery of 
important new biology and the development 
of therapeutic strategies. The HCA is 
catalyzing this paradigm shift by establishing 
reference maps of all human cells, for the 
first time providing a detailed molecular 
picture of the human body. In vitro 
models such as organoids will complement 
these efforts by enabling researchers to 
functionally dissect and systematically 
perturb human biological systems. In 
the context of the HCA, the EU H2020 
HCA|Organoid project is committed to 
establishing a practically useful and readily 
extensible initial version of the Organoid 
Cell Atlas within two years, while extensive 
further work will be needed to maximize the 
impact of the Organoid Cell Atlas for basic 
biology and biomedical applications. Beyond 
the initial focus on colon and brain, the 
Organoid Cell Atlas will incorporate datasets 
from other organoids and organ systems 
through the HCA data infrastructure and  
in collaboration with the other HCA 
Biological Networks.
The mission of the Organoid Cell Atlas 
is to advance biomedical discovery and the 
development of regenerative therapies by 
supporting and accelerating disease-centric 
research in areas such as rare genetic 
diseases, complex multifactorial diseases 
and precision oncology. This overarching 
goal can be achieved by creating an open 
and inclusive research environment that 
facilitates collaboration among a broad 
range of interested researchers, bridging 
communities and integrating expertise in 
organoids and single-cell technology. ❐
Editorial note: This article has been peer 
reviewed.
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